Dmitriy Zamarin

15.2k total citations · 5 hit papers
145 papers, 7.1k citations indexed

About

Dmitriy Zamarin is a scholar working on Oncology, Immunology and Reproductive Medicine. According to data from OpenAlex, Dmitriy Zamarin has authored 145 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 87 papers in Oncology, 40 papers in Immunology and 40 papers in Reproductive Medicine. Recurrent topics in Dmitriy Zamarin's work include Cancer Immunotherapy and Biomarkers (47 papers), Ovarian cancer diagnosis and treatment (39 papers) and Virus-based gene therapy research (33 papers). Dmitriy Zamarin is often cited by papers focused on Cancer Immunotherapy and Biomarkers (47 papers), Ovarian cancer diagnosis and treatment (39 papers) and Virus-based gene therapy research (33 papers). Dmitriy Zamarin collaborates with scholars based in United States, United Kingdom and Ireland. Dmitriy Zamarin's co-authors include Peter Palese, Jedd D. Wolchok, Rikke Holmgaard, Taha Merghoub, James P. Allison, Adolfo Garcı́a-Sastre, David H. Munn, Mena Mansour, Terrence M. Tumpey and Mila B. Ortigoza and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

Dmitriy Zamarin

135 papers receiving 6.9k citations

Hit Papers

Localized Oncolytic Virotherapy Overcomes Systemic Tumor ... 2013 2026 2017 2021 2014 2013 2015 2020 2020 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
    2014 564 citations Dmitriy Zamarin, Taha Merghoub et al. profile →
  2. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
    2013 522 citations Dmitriy Zamarin, Jedd D. Wolchok et al. profile →
  3. Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner
    2015 371 citations Dmitriy Zamarin, Taha Merghoub et al. profile →
  4. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine
    2020 335 citations Mathieu Gigoux, Levi Mangarin et al. profile →
  5. Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study
    2020 224 citations Dmitriy Zamarin, Robert A. Burger et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dmitriy Zamarin United States 39 3.0k 2.8k 2.1k 1.7k 1.5k 145 7.1k
Peter J. van den Elsen Netherlands 57 6.3k 2.1× 2.0k 0.7× 623 0.3× 3.0k 1.8× 1.3k 0.9× 193 9.8k
John E. Janik United States 44 3.0k 1.0× 3.4k 1.2× 614 0.3× 1.8k 1.1× 1.0k 0.7× 142 7.5k
Akifumi Takaori‐Kondo Japan 42 1.9k 0.6× 1.2k 0.4× 861 0.4× 2.3k 1.3× 408 0.3× 288 5.8k
Nancy C. Reich United States 52 3.5k 1.2× 3.9k 1.4× 772 0.4× 3.5k 2.1× 1.1k 0.7× 93 7.7k
Yuji Ohtsuki Japan 36 1.9k 0.6× 1.4k 0.5× 858 0.4× 1.7k 1.0× 222 0.2× 263 5.9k
David Reisman United States 37 634 0.2× 2.5k 0.9× 1.0k 0.5× 3.8k 2.3× 585 0.4× 93 5.9k
Elisabeth H. Weiss Germany 44 3.9k 1.3× 549 0.2× 724 0.3× 1.4k 0.8× 463 0.3× 133 5.9k
Christoph Huber Germany 45 5.0k 1.7× 3.5k 1.2× 455 0.2× 3.3k 2.0× 904 0.6× 155 8.6k
Steven M. Ruben United States 28 2.5k 0.8× 2.6k 0.9× 377 0.2× 3.2k 1.9× 762 0.5× 39 7.4k
Sheng Zhou United States 32 490 0.2× 2.5k 0.9× 415 0.2× 2.6k 1.5× 691 0.5× 84 5.3k

Countries citing papers authored by Dmitriy Zamarin

Since Specialization
Citations

This map shows the geographic impact of Dmitriy Zamarin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dmitriy Zamarin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dmitriy Zamarin more than expected).

Fields of papers citing papers by Dmitriy Zamarin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dmitriy Zamarin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dmitriy Zamarin. The network helps show where Dmitriy Zamarin may publish in the future.

Co-authorship network of co-authors of Dmitriy Zamarin

This figure shows the co-authorship network connecting the top 25 collaborators of Dmitriy Zamarin. A scholar is included among the top collaborators of Dmitriy Zamarin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dmitriy Zamarin. Dmitriy Zamarin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Filippova, Olga T., Arnaud Da Cruz Paula, Vance Broach, et al.. (2024). Molecular and microenvironmental landscapes of human papillomavirus-independent invasive squamous cell carcinoma of the vulva. International Journal of Gynecological Cancer. 35(2). 100051–100051. 2 indexed citations
2.
Rios‐Doria, Eric, Nadeem R. Abu‐Rustum, Gretchen Glaser, et al.. (2024). 2009 International Federation of Gynecology and Obstetrics (FIGO) stage IIIA endometrial cancer: oncologic outcomes based on involvement of adnexa, serosa, or both. International Journal of Gynecological Cancer. 34(10). 1580–1587.
3.
Fang, Yiming, Ji Wang, Subramanyam Dasari, et al.. (2024). Cancer associated fibroblasts serve as an ovarian cancer stem cell niche through noncanonical Wnt5a signaling. npj Precision Oncology. 8(1). 7–7. 23 indexed citations
4.
Davar, Diwakar, Benedito A. Carneiro, Grace K. Dy, et al.. (2024). Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV–GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 12(11). e009336–e009336. 9 indexed citations
5.
Longhini, Ana Leda F., Ryan Kahn, Shirin Issa Bhaloo, et al.. (2023). Surgical stress promotes IL-6–driven tumor progression in ovarian cancer (047). Gynecologic Oncology. 176. S39–S40.
6.
Kahn, Ryan, Bharat Burman, Shirin Issa Bhaloo, et al.. (2023). Oncolytic immunotherapy with recombinant Newcastle disease virus-encoding interleukin-12 in ovarian cancer mouse models (046). Gynecologic Oncology. 176. S39–S39.
7.
Manning‐Geist, Beryl, Sacha Gnjatic, Carol Aghajanian, et al.. (2023). Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission. Cancers. 15(5). 1458–1458. 12 indexed citations
8.
9.
10.
Al-Rawi, Duaa H., Vicky Makker, Britta Weigelt, et al.. (2022). GermlineSMARCA4Deletion as a Driver of Uterine Cancer: An Atypical Presentation. JCO Precision Oncology. 6(6). e2200349–e2200349. 3 indexed citations
11.
Ethier, Josée-Lyne, Katherine C. Fuh, Rebecca C. Arend, et al.. (2022). State of the Biomarker Science in Ovarian Cancer: A National Cancer Institute Clinical Trials Planning Meeting Report. JCO Precision Oncology. 6(6). e2200355–e2200355. 4 indexed citations
12.
Stasenko, Marina, Oladapo Yeku, Kay J. Park, et al.. (2021). Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies. Scientific Reports. 11(1). 3718–3718. 24 indexed citations
13.
Zamarin, Dmitriy, Omid Hamid, Asha Nayak-Kapoor, et al.. (2020). Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study. Clinical Cancer Research. 26(17). 4531–4541. 52 indexed citations
14.
Zamarin, Dmitriy, Robert A. Burger, Michael W. Sill, et al.. (2020). Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study. Journal of Clinical Oncology. 38(16). 1814–1823. 224 indexed citations breakdown →
15.
Reidy‐Lagunes, Diane, Leonard B. Saltz, Michael A. Postow, et al.. (2020). Recommendations for Testing and Treating Outpatient Cancer Patients in the Era of COVID-19. JNCI Journal of the National Cancer Institute. 113(7). 820–822. 5 indexed citations
16.
Ricca, Jacob, Anton Oseledchyk, Tyler Walther, et al.. (2018). Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy. Molecular Therapy. 26(4). 1008–1019. 111 indexed citations
17.
Zamarin, Dmitriy, Jacob Ricca, Svetlana Sadekova, et al.. (2018). PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. Journal of Clinical Investigation. 128(4). 1413–1428. 120 indexed citations
18.
Zamarin, Dmitriy & Sari Pesonen. (2015). Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data. Human Gene Therapy. 26(8). 538–549. 17 indexed citations
19.
Snyder, Alexandra, Dmitriy Zamarin, & Jedd D. Wolchok. (2015). Immunotherapy of Melanoma. Progress in tumor research. 42. 22–29. 13 indexed citations
20.
Ding, Yaozhong, Lihui Qin, Dmitriy Zamarin, et al.. (2001). Differential IL-10R1 Expression Plays a Critical Role in IL-10-Mediated Immune Regulation. The Journal of Immunology. 167(12). 6884–6892. 76 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Peter J. van den Elsen Breakdown of academic impact, for papers by John E. Janik Breakdown of academic impact, for papers by Akifumi Takaori‐Kondo Breakdown of academic impact, for papers by Nancy C. Reich Breakdown of academic impact, for papers by Yuji Ohtsuki Breakdown of academic impact, for papers by David Reisman Breakdown of academic impact, for papers by Elisabeth H. Weiss Breakdown of academic impact, for papers by Christoph Huber Breakdown of academic impact, for papers by Steven M. Ruben Breakdown of academic impact, for papers by Sheng Zhou
Rankless by CCL
2026